MURRAY REPORT✉ Free Email News Alerts← power desk
NEWS   /   GLOBAL POWER

"Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs

Photograph accompanying "Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs (source: ZeroHedge)
ZeroHedge — publisher photograph (see original for photographer credit)

"Consider Discontinuing": FDA Slaps "Eye Stroke" Warning On All GLP-1 Weight-Loss Drugs The FDA is requiring the makers of every GLP-1 drug on the U.S. market, Ozempic, Wegovy, Mounjaro and Zepbound among them, to warn of a potential increased risk of an "eye stroke" that can cause sudden, permanent vision loss in one eye.

The condition is non-arteritic anterior ischemic optic neuropathy, or NAION. The agency's Nov. 9 drug safety communication puts the language in the Warnings and Precautions section of labels for a dozen products, from Byetta, approved in 2005, to Lilly's newly approved Foundayo.

FDA said it "concluded that there is a potential increased risk of rare NAION events in patients taking GLP-1 RAs" and told clinicians to consider discontinuing the drug in patients who develop NAION, unless the benefits clearly outweigh the risk.